Validation of SARS-CoV-2 Detection Assay
Corresponding Organization :
Other organizations : Fujita Health University, National Institute of Infectious Diseases, Fujita Health University Hospital
Variable analysis
- 22 respiratory pathogens used in the initial validation analysis
- Specificity of the study primers
- Presence of MERS-CoV EMC strain provided by Dr. Ron A. M. Fouchier, Erasmus Medical Center, Rotterdam, the Netherlands
- Presence of SARS-CoV Frankfurt 1 strain provided by J. Ziebuhr, University of Würzburg, Germany
- Presence of clinical isolates of human coronaviruses (HCoV)-HKU1, -OC43, -NL63, and -229E described by previous studies
- Use of in vitro-transcribed RNA (GenBank accession number MN908947) to determine the detection limit of the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan)
- MERS-CoV EMC strain
- SARS-CoV Frankfurt 1 strain
- Clinical isolates of human coronaviruses (HCoV)-HKU1, -OC43, -NL63, and -229E
- In vitro-transcribed RNA (GenBank accession number MN908947)
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!